/PFE
PFE Stock - Pfizer Inc.
Healthcare|Drug Manufacturers - GeneralNYSE
$25.20+0.62%
+$0.15 (+0.62%) • Dec 19
72
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.55
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).80
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+15.1%upside
Target: $29.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for PFE
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$24.94 – $25.45
TARGET (TP)$29.00
STOP LOSS$23.18
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.42
52W High$27.69
52W Low$20.92
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $63.63B | $59.55B | $100.33B | $81.29B | $41.65B |
| Gross Profit | $41.85B | $30.34B | $62.09B | $46.88B | $29.88B |
| Gross Margin | 65.8% | 50.9% | 61.9% | 57.7% | 71.7% |
| Operating Income | $16.48B | $5.29B | $37.55B | $20.79B | $9.09B |
| Net Income | $8.02B | $2.13B | $31.36B | $22.15B | $9.16B |
| Net Margin | 12.6% | 3.6% | 31.3% | 27.2% | 22.0% |
| EPS | $1.42 | $0.38 | $5.59 | $3.95 | $1.65 |
Company Overview
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
8
36%
Hold / Neutral
13
59%
Sell / Underperform
1
5%
Analyst Consensus🔴 Bearish
8 Bullish14 Neutral/Bearish
Price Targets
$40
Average Target
↑ 60.0% Upside
Now
$24
Low
$40
Average
$60
High
Based on 23 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 2nd 2025 | Citigroup | Resumed | Neutral | $26 |
| November 13th 2025 | Scotiabank | Initiation | Sector Outperform | $30 |
| April 22nd 2025 | Cantor Fitzgerald | Initiation | Neutral | $24 |
| December 10th 2024 | BofA Securities | Resumed | Neutral | $29 |
| November 15th 2024 | Wolfe Research | Initiation | Underperform | $25 |
| October 25th 2024 | Citigroup | Resumed | Neutral | $30 |
| October 17th 2024 | Bernstein | Initiation | Market Perform | $32 |
| August 7th 2024 | Daiwa Securities | Upgrade | Outperform | - |
| March 22nd 2024 | Argus | Downgrade | Hold | - |
| February 23rd 2024 | Guggenheim | Initiation | Buy | $36 |
| January 4th 2024 | TD Cowen | Downgrade | Market Perform | $32 |
| October 20th 2023 | UBS | Resumed | Neutral | $34← $36 |
| October 16th 2023 | Jefferies | Upgrade | Buy | $39← $38 |
| July 17th 2023 | JP Morgan | Reiterated | Neutral | $41← $45 |
| July 14th 2023 | HSBC Securities | Initiation | Buy | $50 |
Earnings History & Surprises
PFEBeat Rate
100%
Last 18 quarters
Avg Surprise
+37.6%
EPS vs Estimate
Beats / Misses
18/0
Last 12 quarters
Latest EPS
$0.87
Q4 2025
EPS Surprise History
Q1 24
+152.6%
$0.10vs$-0.19
Q2 24
+58.9%
$0.82vs$0.52
Q3 24
+31.0%
$0.60vs$0.46
Q4 24
+72.6%
$1.06vs$0.61
Q1 25
+33.6%
$0.63vs$0.47
Q2 25
+38.1%
$0.92vs$0.67
Q3 25
+34.5%
$0.78vs$0.58
Q4 25
+37.4%
$0.87vs$0.63
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 27, 2026 | — | — | — | — |
Q1 2026 | Feb 3, 2026 | $0.59 | — | — | — |
Q4 2025 | Nov 4, 2025 | $0.63 | $0.87 | +37.4% | ✓ BEAT |
Q3 2025 | Aug 5, 2025 | $0.58 | $0.78 | +34.5% | ✓ BEAT |
Q2 2025 | Apr 29, 2025 | $0.67 | $0.92 | +38.1% | ✓ BEAT |
Q1 2025 | Feb 4, 2025 | $0.47 | $0.63 | +33.6% | ✓ BEAT |
Q4 2024 | Oct 29, 2024 | $0.61 | $1.06 | +72.6% | ✓ BEAT |
Q3 2024 | Jul 30, 2024 | $0.46 | $0.60 | +31.0% | ✓ BEAT |
Q2 2024 | May 1, 2024 | $0.52 | $0.82 | +58.9% | ✓ BEAT |
Q1 2024 | Jan 30, 2024 | $-0.19 | $0.10 | +152.6% | ✓ BEAT |
Q4 2023 | Oct 31, 2023 | $-0.32 | $-0.17 | +46.9% | ✓ BEAT |
Q3 2023 | Aug 1, 2023 | $0.56 | $0.67 | +19.6% | ✓ BEAT |
Q2 2023 | May 2, 2023 | $0.98 | $1.23 | +25.5% | ✓ BEAT |
Q1 2023 | Jan 31, 2023 | $1.05 | $1.14 | +8.6% | ✓ BEAT |
Q4 2022 | Nov 1, 2022 | $1.39 | $1.78 | +28.1% | ✓ BEAT |
Q3 2022 | Jul 28, 2022 | $1.78 | $2.04 | +14.6% | ✓ BEAT |
Q2 2022 | May 3, 2022 | $1.47 | $1.67 | +13.6% | ✓ BEAT |
Q1 2022 | Feb 8, 2022 | $0.85 | $1.08 | +27.1% | ✓ BEAT |
Q4 2021 | Nov 2, 2021 | $1.09 | $1.34 | +22.9% | ✓ BEAT |
Q3 2021 | Jul 28, 2021 | $0.97 | $1.07 | +10.3% | ✓ BEAT |
Latest News
President Trump Says The 3 Of The 17 Pharmaceutical Companies Who Have Not Agreed Are Coming In Next Week
➖ NeutralBenzinga•Dec 19, 2025, 07:30 PM•Also: , ,
Pfizer India And Cipla Announce Exclusive Partnership To Market And Distribute Pfizer Medicines Across India
📈 PositiveBenzinga•Dec 19, 2025, 09:21 AM
Trump Administration Proposes Rule Banning Medicaid And CHIP From Paying For Gender Affirming Care
➖ NeutralBenzinga•Dec 18, 2025, 04:27 PM•Also: , ,
Morgan Stanley Maintains Equal-Weight on Pfizer, Lowers Price Target to $27
📉 NegativeBenzinga•Dec 17, 2025, 03:30 PM
Astellas And Pfizer Announces Topline Results From Interim Analysis Of Phase 3 EV-304 Clinical Trial For PADCEV In Combination With Keytruda; Trial Met Its Primary Endpoint
📈 PositiveBenzinga•Dec 17, 2025, 11:54 AM•Also:
'Secretary Kennedy Adds Duchenne Muscular Dystrophy, Metachromatic Leukodystrophy To Newborn Screenings' - HHS
📈 PositiveBenzinga•Dec 16, 2025, 04:34 PM•Also: , ,
Pfizer shares are trading lower after the company issued soft FY26 guidance.
📉 NegativeBenzinga•Dec 16, 2025, 04:15 PM
Pfizer Expects ~$17B In Annual Revenue Hit From LOE Products By 2030
📉 NegativeBenzinga•Dec 16, 2025, 01:31 PM
Pfizer Plans To Advance 15 Clinical Trials In 2026
📈 PositiveBenzinga•Dec 16, 2025, 01:23 PM
Pfizer Affirms FY2025 Adj EPS Guidance of $3.00-$3.15 vs $3.14 Est; Narrows FY2025 Sales Guidance from $61B-$64B to Approx $62B vs $62.475B Est
➖ NeutralBenzinga•Dec 16, 2025, 11:51 AM
Pfizer Sees FY2026 Adj EPS $2.80-$3.00 vs $3.06 Est; Sees Sales $59.500B-$62.500B vs $61.653B Est
➖ NeutralBenzinga•Dec 16, 2025, 11:49 AM
'FDA Chief Says No Plans To Put Boxed Warning On Covid Vaccines' - Bloomberg News
📈 PositiveBenzinga•Dec 15, 2025, 09:49 PM•Also: , ,
B of A Securities Maintains Neutral on Pfizer, Lowers Price Target to $28
📉 NegativeBenzinga•Dec 15, 2025, 01:26 PM
Adaptive Biotechnologies Announces 2 Immune Receptor Licensing Agreements With Pfizer; Co Gets Undisclosed Upfront Payment, Potential Commercial And Sales Milestones Of Up To $890M
📈 PositiveBenzinga•Dec 15, 2025, 01:03 PM•Also:
Morgan Stanley Maintains Equal-Weight on Pfizer, Lowers Price Target to $28
📉 NegativeBenzinga•Dec 12, 2025, 05:23 PM
Ideaya Biosciences Completed Its Targeted Full Enrollment of 435 Patients In Phase 2/3 OptimUM-02 Trial of Darovasertib Combined With Pfizer's Crizotinib for HLA*A2-Negative Metastatic Uveal Melanoma; Median Progression-free Survival Data is Expected in Q1 2026
📈 PositiveBenzinga•Dec 11, 2025, 11:08 AM•Also:
'Pfizer Will Reduce Its Workforce In Switzerland To Roughly 70 By The End Of This Year From 300' - Bloomberg
📉 NegativeBenzinga•Dec 10, 2025, 04:33 PM
'Pfizer Is Cutting Hundreds Of Jobs In Switzerland To Lower Costs' - Bloomberg News
📉 NegativeBenzinga•Dec 10, 2025, 04:30 PM
Pfizer Reports Results From Phase 3 HER2CLIMB-05 Trial, TUKYSA, Trastuzumab, And Pertuzumab Cuts Risk of Disease Progression or Death by 36% in Phase 3 HER2+ Metastatic Breast Cancer Study
📈 PositiveBenzinga•Dec 10, 2025, 01:17 PM
Reuters Issues Correction: U.S. FDA Says "Doing A Thorough Investigation, Across Multiple Age Groups, Of Deaths Potentially Related To Covid Vaccines"
📉 NegativeBenzinga•Dec 9, 2025, 08:54 PM•Also: , ,
Frequently Asked Questions about PFE
What is PFE's current stock price?
Pfizer Inc. (PFE) is currently trading at $25.20 per share. The stock has moved +0.62% today.
What is the analyst price target for PFE?
The average analyst price target for PFE is $29.00, based on 1 analyst.
What sector is Pfizer Inc. in?
Pfizer Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - General industry. The company is traded on the NYSE exchange.
What is PFE's market cap?
Pfizer Inc. has a market capitalization of $143.25 billion, making it a large-cap company.
Does PFE pay dividends?
No, Pfizer Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAMGN
Amgen Inc.
$327.38
Mkt Cap: $176.3B
BMY
Bristol-Myers Squibb Company
$54.19
Mkt Cap: $110.3B
BSX
Boston Scientific Corporation
$95.61
Mkt Cap: $141.7B
DHR
Danaher Corporation
$224.84
Mkt Cap: $161.1B
GILD
Gilead Sciences, Inc.
$124.29
Mkt Cap: $154.2B
GSK
GSK plc
$48.61
Mkt Cap: $98.8B
MRK
Merck & Co., Inc.
$101.09
Mkt Cap: $254.1B
NVO
Novo Nordisk A/S
$48.09
Mkt Cap: $213.8B
SNY
Sanofi
$48.18
Mkt Cap: $117.4B
SYK
Stryker Corporation
$355.20
Mkt Cap: $135.8B
Explore stocks similar to PFE for comparison